Cargando…

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis

Multiple sclerosis (MS) is a complex disease of the central nervous system that can cause permanent disability in young adults. A large armamentarium is available for its management and is increasing over time. Ozanimod is an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fronza, Marzia, Lorefice, Lorena, Frau, Jessica, Cocco, Eleonora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123972/ https://www.ncbi.nlm.nih.gov/pubmed/34007159 http://dx.doi.org/10.2147/DDDT.S240861

Ejemplares similares

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Menopausal transition in multiple sclerosis: relationship with disease activity and brain volume measurements
por: Lorefice, Lorena, et al.
Publicado: (2023)

Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers
por: Fenu, Giuseppe, et al.
Publicado: (2021)

Ozanimod for multiple sclerosis
Publicado: (2021)

Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World
por: Frau, Jessica, et al.
Publicado: (2021)

Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study
por: Lorefice, Lorena, et al.
Publicado: (2021)

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
por: Lorefice, Lorena, et al.
Publicado: (2023)

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2020)

Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers
por: Pau, Massimiliano, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
por: Pau, Massimiliano, et al.
Publicado: (2022)

The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility
por: Lorefice, Lorena, et al.
Publicado: (2021)

Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers
por: Fenu, G., et al.
Publicado: (2018)

Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives
por: Lorefice, Lorena, et al.
Publicado: (2023)

The Role of Microorganisms in the Etiopathogenesis of Demyelinating Diseases
por: Frau, Jessica, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2023)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis
por: Coghe, Giancarlo, et al.
Publicado: (2019)

What do multiple sclerosis patients and their caregivers perceive as unmet needs?
por: Lorefice, Lorena, et al.
Publicado: (2013)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsing–Remitting and Primary Progressive Multiple Sclerosis
por: Murgia, Federica, et al.
Publicado: (2020)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

(1)H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population
por: Cocco, Eleonora, et al.
Publicado: (2013)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients
por: Pitzalis, Maristella, et al.
Publicado: (2021)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Sex Hormones as Key Modulators of the Immune Response in Multiple Sclerosis: A Review
por: Murgia, Federica, et al.
Publicado: (2022)

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Optical coherence tomography angiography in multiple sclerosis: A cross-sectional study
por: Farci, Roberta, et al.
Publicado: (2020)

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits
por: Thöne, Jan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2uou0lbrhukjv8tpp47i62cv07